Arrowhead Pharmaceuticals, Inc. (ARWR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Arrowhead Pharmaceuticals, Inc. (ARWR) is up 23.5% since the beginning of the year. At $82 per share, ARWR is trading 3.0% below its 52-week high of $85. Investors who bought $1,000 worth of ARWR shares 5 years ago would now be looking at an investment worth $931.

Arrowhead Pharmaceuticals, Inc. (ARWR) has returned 23.51% so far this year and 435.25% over the past 12 months. Looking at the last ten years, ARWR has achieved an annualized return of 31.09%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Jan 6, 1997, ARWR's average daily return is +0.42%, while the average monthly return is +4.42%. At this rate, an investment would double in approximately 1.3 years.

Historically, 44% of months were positive and 56% were negative. The best month was Jan 2004 with a return of +438.5%, while the worst month was Nov 2016 at -75.2%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 10 months.

On a daily basis, ARWR closed higher 36% of trading days. The best single day was May 30, 2002 with a return of +300.4%, while the worst single day was May 24, 2002 at -85.7%.

Arrowhead Pharmaceuticals, Inc. has an annualized alpha of 165.26%, beta of 0.80, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since January 06, 1997.

• This stock participated in 143.29% of S&P 500 Index downside but only 111.82% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ARWR ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Arrowhead Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arrowhead Pharmaceuticals, Inc. was 99.24%, occurring on Dec 16, 2016. The portfolio has not yet recovered.

The current Arrowhead Pharmaceuticals, Inc. drawdown is 49.54%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Arrowhead Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Arrowhead Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.